Assisted Reproductive Technology Market – Trends Forecast Till 2031

Market Snapshot

Market Overview

The global Assisted Reproductive Technology Market size was estimated at USD 27,489.0 million in 2024 and is projected to reach USD 40,790.46 million in 2031 at a CAGR of 5.8 % during the forecast period 2025-2031.

The assisted reproductive technology (ART) market refers to the range of medical technologies and procedures that assist individuals or couples in achieving pregnancy. These technologies include in vitro fertilization (IVF), intrauterine insemination (IUI), egg/sperm donation, and surrogacy, among others. ART aims to address infertility issues, offering solutions for both male and female reproductive challenges. It involves advanced medical interventions, combining scientific advancements with personalized care to improve the chances of conception for individuals facing infertility or related issues.

The scope of the ART market covers various procedures and services, including diagnostic tools, fertility drugs, and the provision of assisted conception services. It is used by a wide range of demographics, including couples with infertility, single women, and same-sex couples. The market spans fertility clinics, hospitals, and specialized reproductive health centers. With the growing acceptance of ART and its increasing availability, it is becoming more accessible across the globe, especially in regions where advanced healthcare infrastructure supports these services.

Trends in the ART market reflect a greater emphasis on personalization and patient-centered care, with advancements in genetics, cryopreservation, and egg freezing gaining traction. The use of AI and big data analytics is improving treatment success rates by providing more accurate predictions and individualized treatment plans. Additionally, the rise of fertility preservation options for women and the increasing popularity of egg donation and surrogacy are driving market expansion. There is also a growing trend towards global fertility tourism, where patients travel to countries with more affordable ART services.

The key drivers of the ART market include the rising prevalence of infertility, lifestyle factors such as delayed marriage and childbearing, and increased awareness of ART options. Technological advancements, regulatory support, and rising healthcare investments are further fueling the market’s growth. As societal attitudes continue to evolve and demand for reproductive health services increases, the ART market is poised for continued growth, offering innovative solutions to help individuals and couples achieve their family-building goals.

Impacts USA tariff rates on the Assisted Reproductive Technology Market

​The 2025 U.S. tariffs introduced by President Donald Trump have notably impacted the Assisted Reproductive Technology (ART) market by increasing the cost of essential medical devices and pharmaceuticals. Tariffs on imports from key manufacturing countries have led to higher prices for critical components used in ART procedures, such as incubators, cryopreservation media, and fertility medications. This escalation in costs has compelled ART providers to either absorb the additional expenses, thereby reducing profit margins, or pass them on to patients, potentially limiting access to fertility treatments. Furthermore, the tariffs have disrupted global supply chains, causing delays in the availability of necessary equipment and medications, which can adversely affect the scheduling and success rates of ART procedures. These challenges have introduced a degree of uncertainty and volatility in the ART market, potentially slowing its growth in the near term.

Delvens Industry Expert's Standpoint

Experts in the Assisted Reproductive Technology Market highlight several key trends driving growth and innovation. The assisted reproductive technology (ART) market involves medical technologies like IVF, IUI, egg/sperm donation, and surrogacy to assist individuals and couples in overcoming infertility challenges. With a focus on personalized care, the market includes fertility clinics, hospitals, and specialized centers, driven by advancements in genetics, cryopreservation, and AI. Rising infertility rates, delayed childbearing, and increasing awareness are key market drivers, while trends such as egg freezing, fertility preservation, and fertility tourism are contributing to its growth. Technological innovations and broader societal acceptance are shaping the ART market, making reproductive healthcare more accessible and diverse.

Analyst view on the impacts of U.S. tariff rates on the Assisted Reproductive Technology Market

Despite these challenges, the ART market is anticipated to maintain long-term growth, driven by factors such as increasing infertility rates, advancements in reproductive technologies, and a growing societal acceptance of ART procedures. The demand for ART services remains robust, as individuals and couples continue to seek solutions for infertility. Moreover, the market is expected to adapt by exploring alternative supply chains and investing in domestic manufacturing to mitigate the impact of tariffs. Innovations in ART, including the development of more efficient and cost-effective procedures, are also likely to contribute to market resilience. As the industry navigates these challenges, it is poised to emerge stronger, with a more diversified and robust infrastructure to support sustained growth.

Market Portfolio

Key Findings

• The assisted reproductive technology (ART) market is anticipated to grow steadily due to the rising infertility rates, advancements in ART success, and increasing disposable income in developing regions. Factors like sexually transmitted infections (STIs), obesity, and conditions like PCOS and endometriosis contribute to the growing prevalence of infertility. As society becomes more accepting of ART, advanced technologies such as Pre-implantation Genetic Testing (PGT), Endometrial Receptivity Analysis (ERA), and magnetic cell sorting are enhancing the demand for ART procedures. Additionally, research innovations in culture media and embryo development are further supporting industry growth.

• In terms of procedure types, IVF dominates the market, with frozen non-donor procedures seeing significant growth due to their benefits in treating male infertility and fallopian tube issues. Artificial insemination, particularly intrauterine insemination, is also expected to experience strong growth, especially among same-sex couples and single women seeking fertility treatments. The fertility clinic segment leads in terms of revenue share and is expected to continue growing rapidly due to the specialization and expertise offered in ART procedures, while hospitals are becoming increasingly popular in low- and middle-income countries due to their accessibility.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such as increasing infertility rates, advancements in ART technologies, rising acceptance, legalization of same-sex marriages, fertility research investments, awareness, clinic expansion, AI integration, supportive policies, delayed parenthood, improved success rates, fertility benefits, rising male infertility, and telehealth adoption have triggered the Assisted Reproductive Technology Market in the region.

Regional Analysis

North America to Dominate the Market

• North America, particularly the United States, holds a significant share of the global ART market. This dominance is driven by factors such as high infertility rates, increasing maternal age, and advanced healthcare infrastructure. However, recent legal challenges, including state-level restrictions on IVF practices, have introduced uncertainties, potentially impacting accessibility and affordability. Despite these challenges, the region continues to lead in ART procedures and technological advancements.

• Europe remains a robust market for ART, with countries like Germany, France, and the UK at the forefront. The region benefits from progressive healthcare policies, high success rates in ART procedures, and strong patient demand. However, varying regulations across countries and ethical considerations surrounding ART practices present ongoing challenges. Despite these, Europe's commitment to reproductive health ensures continued market growth.​

• The APAC region is experiencing rapid growth in ART adoption, driven by rising infertility rates, delayed marriages, and increasing awareness. Countries like India and China are witnessing a surge in ART procedures, with India emerging as a hub for fertility tourism due to cost-effective treatments. However, cultural stigmas and regulatory inconsistencies pose challenges to widespread acceptance and accessibility.​

• Latin America is witnessing steady growth in ART adoption, influenced by increasing awareness, improving healthcare infrastructure, and supportive government policies. Countries like Brazil and Mexico are leading the region in ART procedures. However, economic disparities and varying levels of healthcare access across the region can limit the widespread availability of ART services.​

• The MEA region shows a growing interest in ART, particularly in Gulf Cooperation Council (GCC) countries like the UAE and Saudi Arabia, where cultural acceptance and healthcare infrastructure are improving. However, in many African nations, limited awareness, economic constraints, and regulatory barriers hinder the widespread adoption of ART. Despite these challenges, there is a gradual shift towards embracing ART as a viable solution for infertility.

Competitive Landscape

• Cosmos Biomedical Ltd.
• Microm U.K. Ltd.
• CooperSurgical, Inc.
• FUJIFILM Irvine Scientific
• Cryolab Ltd.
• Vitrolife AB
• European Sperm Bank
• Bloom IVF Centre
• Merck KGaA
• Ferring B.V.

Recent Developments

• In January 2024, Ivy Fertility teamed up with fertility specialty pharmacy SMP Pharmacy Solutions to improve the patient experience across Ivy’s 13 fertility centers through a joint co-branding initiative. This strategic partnership aimed to enhance service delivery and offer patients comprehensive support, while also benefiting both companies with stronger offerings and increased patient satisfaction.

• In October 2023, Hamilton Thorne Ltd. acquired Gynetics Medical Products, N.V. and Gynetics Services B.V., a leading manufacturer of innovative, high-quality In-vitro fertilization (IVF) devices. This acquisition broadened Hamilton Thorne's product portfolio, boosting its position and competitive edge in the global IVF market.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Assisted Reproductive Technology Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope